Therapeutic Asset Ratings
228 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tiselizumab
Follicular Lymphoma
Tianjin Medical University Cancer Institute and Hospital
P2
CCC
(48)
Tislelizumab
HER2 Positive Breast Carcinoma
Tianjin Medical University Cancer Institute and Hospital
P2
CCC
(48)
Tuvonralimab
Non-Small Cell Lung Carcinoma
Tianjin Medical University Cancer Institute and Hospital
P2
CCC
(48)
Adebrelimab
Decitabine
Tianjin Medical University Cancer Institute and Hospital
P1/2
CCC
(48)
Decitabine
Decitabine
Tianjin Medical University Cancer Institute and Hospital
P1/2
CCC
(48)
Decitabine
Adebrelimab (SHR-1316)
Tianjin Medical University Cancer Institute and Hospital
P1/2
CC
(47)
Iparomlimab
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
P2
CC
(46)
Anti-Cd70-Car-T Cells
Cutaneous T-cell Lymphoma (CTCL)
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
Anti-Cd70-Car-T Cells
NHL (Non-Hodgkin Lymphoma)
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
Anti-Cd70-Car-T Cells
Relapsed / Refractory Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
cht101
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
cht101
Non-Hodgkin Lymphoma
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
cht101
Relapsed / Refractory Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
cht102
Malignant Pancreatic Neoplasm
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
Cyclophosphamide
Relapsed / Refractory Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
Fludarabine
Relapsed / Refractory Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
Lucar-G39P Cells Product
B-Cell Non-Hodgkin Lymphoma
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
Decitabine
Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
P1/2
CC
(43)
Anti-Cd70-Car-T Cells
Peripheral T-cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
P1
C
(39)
cht101
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Tianjin Medical University Cancer Institute and Hospital
P1
C
(39)
gk01
Neoplasm
Tianjin Medical University Cancer Institute and Hospital
P1
C
(37)
Abesili
Breast Carcinoma
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Calcium folinate pentahydrate
Acute Leukemia
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Calcium folinate pentahydrate
Immune-related Adverse Event
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Calcium folinate pentahydrate
Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Showing 176 to 200 of 228 assets
Previous
Page 8 of 10
Next